script.reportAU
Oncology

Tamoxifen

Brand: Nolvadex-D

PBAC's latest decision on Tamoxifen: Recommended with restriction (2016). Considered for Primary prevention of breast cancer in women at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2016
Submissions
1
2016 → 2016

Eligible population

Women at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average) of developing breast cancer.

Therapy area
Oncology
Line of therapy
First-line
Evidence base
Meta-analysis
Primary endpoint
ORR
Pivotal trial size
28,444 patients
Key trials
IBIS-I, NSABP-1, Marsden, Italian, Cuzick meta-analysis
Comparator
watchful waiting
Economic model
CUA
ICER note
The document states a cost-utility analysis was provided but does not present numeric ICER values in the public text.

Similar precedents

Open on full dashboard →